Psilocybin
Reunion Neuroscience Posts $48 Million Loss Ahead of Acquisition
Reunion Neuroscience is expected to go private later this year.
The post Reunion Neuroscience Posts $48 Million Loss Ahead of Acquisition appeared first…
Toronto-based Reunion Neuroscience (Nasdaq: REUN) (TSX: REUN) reported a $48 million net loss for its 2023 fiscal year, which ended March 31, but the company expressed optimism on its development of a psychedelic treatment for postpartum depression.
Reunion, which was recently purchased by MPM BioImpact for $13 million and is set to go private later this year, reported that its key postpartum drug has thus far been “generally well-tolerated” in clinical trials, a sign that the company is making progress toward bringing some of its work to market.
The drug, RE-104, gives patients a roughly 3.7-hour-long psychedelic trip similar to that of psilocybin, Reunion reported, but with “the same intensity and quality of experience” and “with no serious adverse events.”
A second clinical trial is set for later this year, even as Reunion has been fighting in New Jersey court to protect its patent on RE-104, which it alleged was stolen by competitor Mindset Pharma in its own patent application.
A large part of Reunion’s losses for the 2023 fiscal year were from discontinuing ketamine treatment clinics that were spun out to form Field Trip Health & Wellness in August 2022, which cost Reunion $10.4 million. (Field Trip recently closed or sold most of those clinics, except for two in Canada.)
Reunion also reported that it lost $13.8 million due to lease obligations associated with the Field Trip clinics and a write-off of its equity investment in Field Trip.
At the close of March, Reunion had $27.7 million in the bank, down from $64 million a year prior.
The acquisition by MPM BioImpact is set to close in the third quarter this year, according to Reunion.
The post Reunion Neuroscience Posts $48 Million Loss Ahead of Acquisition appeared first on Green Market Report.
psilocybin ketamine psychedelic depression treatment clinics tsx nasdaq field trip health mindset pharma field trip mindset-
Law & Regulation1 week ago
FDA to weigh safety, impact of MDMA therapy for PTSD at June meeting
-
Psychedelics1 week ago
Numinus Wellness Focused on Boosting Profitability and Expanding Community Support
-
Psychedelics1 week ago
MindMed Reports First Quarter 2024 Financial Results and Business Updates
-
Psilocybin1 week ago
The Psychedelic Scene in Oaxaca, Mexico
-
Psychedelics1 week ago
Oprah Daily’s Comprehensive Guide to Psychedelics: A Milestone for Industry Acceptance
-
Psychedelics1 week ago
Optimi Health Receives Export Permit from Health Canada to Ship MDMA To Tel Aviv University’s Institute for Psychedelic Research
-
Psychedelics1 week ago
The Onion Pokes Fun at Psychedelics
-
Law & Regulation1 week ago
Compass Pathways keeps plugging away with its psilocybin study trials